For Utah independent pharmacies

Utah pharmacies in 2026: MAC appeals, wholesaler costs and the refunds you're owed

The PBM pays below what the drug cost you, the wholesaler's price drifts, and refunds you're owed don't arrive. The rules on all three changed this year. What changed, with the statute text, and what to do about it.

Scruple · October 13, 2026 · Numbered links go to the sources at the end.

1. Utah's new MAC law: 21 days to appeal, 14 business days for an answer

House Bill 527, "Pharmacy Pricing Amendments," passed the House 62 to 1 and the Senate 24 to 0, and took effect May 6, 2026.¹ It rewrote Utah Code 31A-46-303, the section that governs maximum allowable cost (MAC) lists. Here is what a PBM in Utah now owes you.²

Two details. A MAC may only be set for drugs that are therapeutically equivalent and "generally available for purchase in Utah from a national or regional wholesaler," so a drug you can't actually buy at that price is grounds for appeal on its own. And if the PBM can't show the drug is available at the MAC for "a similarly situated pharmacy," it loses the appeal.² The section doesn't cover Medicaid PBMs. Violations carry a penalty of up to $2,500 each, and each day a violation continues counts separately.³

The protections Utah passed in 2020 still stand, and they're the ones to quote when a check comes up short:⁶

• No clawbacks after adjudication except fraud, duplicate payment, or a service not provided (31A-46-304). Audit findings and signed performance contracts are the carve-outs.
• 30 days' notice before any DIR fee that lowers your total compensation, and a report of what was taken within 120 days (31A-46-302).
• No gag clause. You may tell patients the cash price and cheaper alternatives, and a patient pays the lowest of the copay, the claim amount, your reimbursement or the cash price (31A-46-302).
• Parity with the PBM's own pharmacies in aggregate reimbursement (31A-46-305), and no 340B-based cuts (31A-46-309).
• Audits: 10 days' notice, an 18-month lookback, no recoupment for clerical errors, no extrapolation (58-17b-622).

Complaints go to the Utah Insurance Department, which licenses PBMs; its online complaint form has a "PBM/Pharmacy" category.⁷

2. Your wholesaler contract moves your cost more than any single price

Brand drugs are priced as WAC minus a few percent, and that discount is tied to your generic compliance ratio (GCR, generic dollars over total dollars), reviewed quarterly. Generic rebates are paid quarterly too, and the formulas differ by wholesaler. Buying generics off contract from a secondary supplier can look like a win on that invoice and cost you the brand discount and rebate tier at quarter end.⁸ One buying group's rule of thumb: a 0.5% shift in pricing "can cost a typical $4M store about $15,000 annually."⁹

The benchmark everyone uses is NADAC, the national average acquisition cost from a monthly survey of retail pharmacy invoices. Two things about it. It's an average, so by construction some pharmacies pay more than it, and CMS says so in the methodology.¹⁰ And it's an invoice price, so it ignores the quarterly rebates you get later. On brands, NADAC runs around WAC minus 4%, which is below what many independents pay, because the wholesaler itself only gets about 3% off WAC.¹¹ So a brand claim paid at NADAC can be below your cost before the dispensing fee is counted.

What to check on invoices, once a month: unit price per NDC against last month and against NADAC, whether WAC decreases actually showed up on the invoice (NCPA has asked owners to check this since January),¹² and where your GCR sits against the next tier in your contract.

3. Refunds in 2026: who owes you money and when

On that last row: the FTC found the three biggest PBMs' own pharmacies collected more than $7.3 billion above NADAC on specialty generics between 2017 and 2022.¹⁸ Utah's own 2019 legislative audit found PEHP's PBM kept a 24% spread on generics.¹⁹ The remedy regulators keep choosing is cost-plus, and cost-plus means showing the PBM your invoices. Your acquisition cost per NDC is about to be a contract term.

4. The numbers

• Independent gross margin fell to 19.7% in 2023, the lowest in NCPA's ten-year lookback, and 2024 set a ten-year low in gross profit.²⁰
• 2,275 pharmacies closed in the first eight months of 2024; about half were independents or small chains.²¹
• Part D and Medicaid are 52% of an independent's prescriptions, so the MFP and Medicaid rules above touch half your volume.²⁰
• Utah Medicaid pays the lowest of WAC, FUL, NADAC or the state MAC, plus a $11.57 dispensing fee, raised from about $10 in 2024 after a cost-of-dispensing survey found $11.57 was the mean.²²
• In October 2024 one Utah owner told KSL he'd lost about $40,000 in four months to PBM reimbursement.²³

5. What to do, and how often

1. Weekly: list every claim paid below your acquisition cost, group by PBM, file the appeals. The 21-day window starts at adjudication, so a monthly pass misses most of them.
2. Keep every denial. Each one must now name an NDC you could buy at the MAC. Try to buy it. If you can't, that's your next appeal and your complaint to the Insurance Department.
3. Monthly, check the invoice, not the statement: unit price per NDC against last month and NADAC; look for WAC cuts that didn't land; know your GCR against the next tier.
4. Monthly, reconcile MFP refunds against the claims you dispensed on the ten negotiated drugs. Without MTF enrollment and electronic payment, the refunds don't come.
5. Read any new "performance" addendum before signing. Under 31A-46-304 a signed performance contract is the main way a PBM can still take money back.